Bone Biologics Corp (BBLG)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 52/100 (HIGH), 16.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.76% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Bone Biologics Expands Trial Sites
- BBLG Efficiency Improves as Crucial Trials Advance
- Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances
- Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
- BBLG Secures Financing for Critical Trials
- Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
- Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bone Biologics Corp.
Full BBLG Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.